NET Patient Foundation Research Abstracts
NPF and NCRAS Public Health England partnership project has been compiling statistics on the incidence, prevalence and survival of NET patients in England using English cancer registry data, with an aim to also access Scottish, Welsh and Northern Irish cancer registry data to also get UK wide statistics.
We carried out four pieces of research in 2017, abstracts for which can be found below:
- The Incidence and Prevalence of Neuroendocrine Tumours in England.
- The 1- year survival rates for Neuroendocrine tumour patients in England.
- Metachronus primary cancers in Neuroendocrine tumour patients.
- Neuroendocrine Tumour patients experiences of support in the community setting across the treatment trajectory.
Presenting symptoms and delay in diagnosis of gastrointestinal and pancreatic Neuroendocrine tumours
Ileocolonic neuroendocrine tumours identified in the English bowel cancer screening programme
Self-reported side effects in neuroendocrine tumour (NET) patients prescribed somatostatin analogues – the role for specialist dietitians and nurses
- Assess what symptoms/side effects patients report on SSA’s.
- Assess the severity of symptoms/side effects reported by patients whilst on SSA’s.
- Produce recommendations on how to deal with symptoms commonly experienced by patients on SSA’s.
This study has been accepted to be published in the British Journal of Nursing.
Recent News
Leading Experts Emphasise the Crucial Role of Research in Fighting Neuroendocrine Cancer!
Why is research so important? Neuroendocrine cancer is a complex disease, and every step in understanding it takes us closer to accurate diagnosis, prevention, and effective treatment. Over the coming weeks, we will be sharing insightful videos featuring...
Understanding Neuroendocrine Cancer of the Breast
- Neuroendocrine Cancer of the Breast (NECB) is a rare and distinct form of breast cancer, accounting for less than 5% of all breast cancer cases. This unique subtype can be challenging to diagnose and treat, often requiring specialised medical expertise and precise...
TEMPORARY shortage of Creon® 25,000u capsules in the UK
Viatris, the marketing authorisation holder for Creon® in the UK, has informed us that they are currently experiencing a temporary supply constraint of Creon® 25000u capsules: therefore supply wholesalers and local pharmacies may be out of stock. - - The next...